![Getinge AB, Audiocast with teleconference, Q2'24](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/051c381c-a7e1-4700-9aaf-5c6024766550.png)
Getinge
208,8 SEK -0,19%5 investorer følger denne virksomhed
Getinge is a global provider of technical solutions for the healthcare industry. The company is a developer and manufacturer of solutions used in operating rooms, intensive care units, and sterile facilities. The company's products are used, for example, for infection control, among IT systems, patient management, and in the care of severely obese patients. The head office is located in Gothenburg.
Omsætning
-
EBIT %
-
P/E
23,57
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
NASDAQ Stockholm
GETI B
Daglig lav / høj pris
207,4 / 209,9
SEK
Markedsværdi
56,87 mia. SEK
Aktieomsætning
77,6 mio. SEK
Volumen
372 t
Seneste videoer
Finanskalender
Delårsrapport
18.10.2024
Større aktionærerKilde: Millistream Market Data AB
Ejer | Kapital | Stemmer |
---|---|---|
Carl Bennet AB | 20,0 % | 50,1 % |
Fjärde AP-fonden | 7,4 % | 4,6 % |
Premium
This content is for our Premium customers only.
ViserAlle indholdstyper
![Getinge AB, Audiocast with teleconference, Q2'24](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/051c381c-a7e1-4700-9aaf-5c6024766550.png)
Getinge Interim Report April-June 2024: Higher sales, stronger margins and product launches with significant added value for customers
Modular Finance IR Consensus: Getinge – Consensus estimates Q2 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Getinge invites fund managers, analysts, and media to Q2 Report 2024 conference call
![Getinge, Audiocast with teleconference, 2024](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/ddf5a336-5bdb-492f-96c8-9dfba7a27033.png)
Getinge, Audiocast with teleconference, 2024
Getinge's financial target 2024-2028: Adjusted EPS growth of above 12% on average
Getinge invites fund managers, analysts and media to a Capital Market Update conference call
Resolutions at Getinge's Annual General Meeting 22 April 2024
![Getinge AB, Audiocast with teleconference, Q1, 2024](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/48725803-8db0-4670-9e0c-33775f791ed7.png)
Getinge AB, Audiocast with teleconference, Q1, 2024
Getinge Interim Report January-March 2024: Higher sales, strong cash flow and new products creating more customer value
Getinge invites fund managers, analysts, and media to Q1 Report 2024 conference call
Getinge publishes 2023 annual report
Getinge: NOTICE OF ANNUAL GENERAL MEETING IN GETINGE AB (PUBL)
Getinge takes a leap forward in cardiovascular surgery with the 510(k) clearance for Vasoview Hemopro 3
TÜV SÜD is temporarily suspending Getinge's CE certificate for Cardiosave
![Getinge AB, Audiocast with teleconference, Q4, 2023](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/b663d89e-fa6a-475d-ba4f-638b8979ffe3.png)
Getinge AB, Audiocast with teleconference, Q4, 2023
Getinge Year End Report 2023: Strong sales and healthy cash flow - but margins impacted by quality costs and mix effects
Agneta Palmér appointed new CFO of Getinge
Getinge invites fund managers, analysts, and media to Year-End Report 2023 conference call
![Getinge AB, Audiocast with teleconference, Q3, 2023](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/19cff160-ba1e-42bb-b2a0-58c1d3724a71.png)